Area surrounding a tumor impacts how breast cancer cells grow

March 14, 2018 by Amanda Gibbs, Oregon Health & Science University
“Cancer is a complex mixture of cancer cells, normal blood cells, tissue and immune cells. Tumor cells themselves alter the microenvironment to secrete things that help tumors grow,”  says Joe Gray, Ph.D., (left) director of the OHSU Center for Spatial Systems Biomedicine (OCSSB) and the OHSU Knight Cancer Institute associate director for biophysical oncology. (OHSU)

Cancer is typically thought of as a tumor that needs to be removed or an area that needs to be treated with radiation or chemotherapy. As a physicist and cancer researcher, Joe Gray, Ph.D., thinks differently.

"Cancer is complex mixture of cancer , normal blood cells, tissue and immune cells. Tumor cells themselves alter the to secrete things that help tumors grow," he said.

Gray and Jim Korkola, Ph.D., led a team of OHSU researchers to publish a paper in Cell Systems focused on the area around a tumor, called the microenvironment.

"We were interested in exploring a large number of signals from the different cells and components of cancer to understand what they do with therapeutic response," said Gray, the OHSU Knight Cancer Institute associate director for biophysical oncology and professor of in the OHSU School of Medicine.

The HER2 positive microenvironment

The researchers focused on a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2, or HER2, which promotes . This overexpression of HER2 occurs in roughly 25 percent of all breast cancer cases.

Korkola, an assistant professor of biomedical engineering in the OHSU School of Medicine and co-principal investigator, says this is the first comprehensive study of the microenvironment and its influence on HER2 positive cells. He says studying the area surrounding a tumor is important for a number of reasons: "One of those reasons is that there can be a disconnect between how cells behave in simple cell line models and how they behave in patients."

To better understand the cell behavior and response, Korkola and team printed samples, or arrays, of different proteins to produce microenvironment microarrays (MEMA). The researchers used robotic devices to print thousands of microenvironment conditions on a single microscope slide. Printing at that large scale gave them the ability to observe different interactions within the microenvironment and how the cells behave when faced with two different HER2 positive-targeted drug treatments used in patients today: lapatinib and neratinib.

Study results

Using cell lines derived from human tumors, the study team tested around 2,500 combinations of micro-environmental proteins to determine how they would alter the cellular response to the two different HER2-targeted drugs. They studied these effects in two different molecular subtypes of HER2 positive , known as HER2E and L-HER2 positive disease.

The work showed that the tumor microenvironment plays a critical role in altering therapeutic response in HER2-positive breast cancer cell lines, which they were able to further confirm in a mouse model. The results suggest fundamental differences exist in the two breast subtypes, which supports the emerging notion that L-HER2+ and HER2E represent distinct diseases.

In the research paper, Korkola, Gray and team suggest future clinical studies to test the possibility that targeting resistance factors from the microenvironment in both subtypes will improve clinical outcome in patients being treated with HER2-targeted drugs. In fact, the research team is pursuing funding options that would allow preliminary testing in patients, as part of a partnership with expert Zahi Mitri, M.D., an assistant professor of medicine (general internal medicine) in the OHSU School of Medicine, and a biotechnology company.

"This type of research is an important part of a precision oncology effort underway at the Knight Cancer Institute," Gray said. "Our goal is to develop therapeutic strategies that are more durable—and tolerable—for patients."

Bringing together the right team

Gray says the impetus for this research project—including the new use of MEMA—dates back to 2012. "If you're going to bring on a new way of measuring things, you have to make the platform work, develop the analytical tools to interpret the data and do the experiment," he said. "There is a significant gestation time to build and test a useful platform."

And in order to effectively build a new testing platform, it takes a multidisciplinary team.

"It's not possible for a single small lab to pull off an experiment of this complexity. We brought together biologists, people who run the robotics, imaging experts and computational biology experts," Korkola said. "In fact, these experiments formed the bulk of the Ph.D. thesis of Spencer Watson, the lead author. He did a superb job and is now pursuing his post-doc in Switzerland. Without the team effort, we never would have been able to make the discoveries we report in the paper."

Gray also emphasizes the important role the Susan G. Komen Foundation played in this research. "They were one of the real drivers of the project, along with the NIH," he said. "They played an integral role in helping us to develop this new line of research." He added the data and tools used in this study are publicly available on a website hosted by the National Institutes of Health LINCS consortium.

Explore further: Brain microenvironment makes HER2-positive breast cancer metastases resistant to treatment

More information: Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes, Cell Systems (2018). DOI: 10.1016/j.cels.2018.02.001 , http://www.cell.com/cell-systems/fulltext/S2405-4712(18)30054-1

Related Stories

Brain microenvironment makes HER2-positive breast cancer metastases resistant to treatment

May 24, 2017
While target therapies directed toward genetic mutations that drive a tumor's growth have significantly improved the outlook for many patients, they have not been as successful in controlling brain metastases in several types ...

Researchers find protein that mediates formation of HER2-driven breast cancer

January 9, 2018
Researchers at the University of Cincinnati College of Medicine have identified for the first time that the estrogen receptor-binding protein MED1 is a critical mediator of HER2-driven breast cancer, identifying it as a potential ...

Attacking metastatic tumors in the brain

June 5, 2017
Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has discovered a novel mechanism behind the ...

Breast cancer cells found to switch molecular characteristics

August 24, 2016
A study led by Massachusetts General Hospital (MGH) investigators reveals how spontaneous changes in the molecular characteristics of tumors can lead to tumors with a mixed population of cells requiring treatment with several ...

New study shows targeted therapy needed for breast cancer with brain metastases

December 7, 2016
Researchers at the University of Pittsburgh Cancer Institute (UPCI) and Magee-Womens Research Institute (MWRI) have discovered molecular changes in the primary tumor of breast cancer patients who developed brain metastases. ...

Recommended for you

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

Researchers create novel combination as potential therapy for high-risk neuroblastoma

June 18, 2018
Researchers at VCU Massey Cancer Center in Richmond, Virginia, have identified a promising target to reverse the development of high-risk neuroblastoma and potentially inform the creation of novel combination therapies for ...

Standard myelofibrosis drug can awaken 'dormant' lymphoma

June 18, 2018
Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life ...

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

LaPortaMA
not rated yet Mar 14, 2018
No one has every determined if BC ( or most any other mytotic disease ) is a systemic disease with local manifestations, or a local disease systemic maniefestations.
Ruefully, the average area around the tumor is 70KG/1.71 m^2.
LaPortaMA
not rated yet Mar 14, 2018
No one has every determined if BC ( or most any other mytotic disease ) is a systemic disease with local manifestations, or a local disease systemic maniefestations.
Ruefully, the average area around the tumor is 70KG/1.71 m^2.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.